SCHEMBL30848017

SCHEMBL30848017

CN(C)c1ccc2cnn(C)c2c1NS(=O)(=O)c1cnn(-c2ccnc(C(F)(F)F)c2)c1

nearest known ligand 0.33

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 2/20 0.33
▸ GRIN1 Q05586 2/20 0.33
▸ GRIN2B Q13224 2/20 0.33
▸ PTGS2 P35354 4/20 0.32
▸ PTGS1 P23219 3/20 0.32
▸ AR P10275 1/20 0.31
▸ OXTR P30559 1/20 0.31
▸ AVPR1A P37288 1/20 0.31
▸ NTRK1 P04629 1/20 0.31
▸ FLT3 P36888 1/20 0.31
▸ CHRM4 P08173 1/20 0.31
▸ PIK3CA P42336 1/20 0.31
▸ MTOR P42345 1/20 0.31
▸ BRD4 O60885 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27132351 1.00 RXRA (0.33) RXRAGRIN1GRIN2BPTGS2PTGS1
SCHEMBL27132783 0.88 RXRA (0.36) RXRAGRIN1GRIN2BPTGS2AR
SCHEMBL30848042 0.88 RXRA (0.36) RXRAGRIN1GRIN2BPTGS2AR
SCHEMBL27132346 0.87 RXRA (0.38) RXRAGRIN1GRIN2BPTGS2PTGS1
SCHEMBL30848041 0.87 RXRA (0.38) RXRAGRIN1GRIN2BPTGS2PTGS1
SCHEMBL27132348 0.86 SLC40A1 (0.38) RXRAGRIN1GRIN2BPTGS2PTGS1
SCHEMBL30847993 0.86 SLC40A1 (0.38) RXRAGRIN1GRIN2BPTGS2PTGS1
SCHEMBL30847954 0.85 SCN9A (0.33) RXRAGRIN1GRIN2BAROXTR
SCHEMBL27132405 0.85 SCN9A (0.33) RXRAGRIN1GRIN2BAROXTR
SCHEMBL30847936 0.84 CYP17A1 (0.38) RXRAGRIN1GRIN2BCHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4577536-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY Hotspot Therapeutics, Inc. (US) 2025-07-02 — — EP disclosed
WO-2024044730-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed
Send feedback